Overview

Metformin in Psoriatic Arthritis

Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
Psoriatic arthritis (PsA) is a systemic, inflammatory disease. The chronic inflammation in PsA predisposes patients to the metabolic syndrome (MetS). MetS is associated with systemic inflammation and proinflammatory cytokines. Clinical observations and experimental results argue for an anti-inflammatory and immunosuppressant property of MET.
Phase:
N/A
Details
Lead Sponsor:
Faculty of Medicine, University of Alexandria
University of Alexandria
Treatments:
Metformin